[ad_1]
July 8, 2019
PhoreMost, a UK-based biopharmaceutical company dedicated to the management of "non-drug" disease targets, today announced that it has signed a collaborative agreement focused on structural biology with the Center for Chemical Biology and therapeutic (CCBT), Bangalore, India.
The CCBT of the Institute for Stem Cell Science and Regenerative Medicine (inStem) is funded by the Biotechnology Department of the Government of India. The goal of this collaboration is the structural visualization of new drug sites on multiple targets, to rapidly advance new treatments.
PhoreMost's Next Generation Phenotypic Screening Platform, SITESEEKER® Probes the entire proteome into a living cell environment for new drug targets, thus allowing routine unmasking of cryptic drug sites.
PhoreMost has built a portfolio of new targets and early drug discovery programs using this platform. This new collaboration will leverage CCBT's expertise in structural and chemical biology to advance selected targets in PhoreMost's discovery portfolio.
CCBT is a state-of-the-art multidisciplinary effort created to launch innovative approaches to create chemical tools that modulate new target clbades. The center integrates biochemistry, genetics and cell biology with structural biology, computational chemistry and synthetic chemistry.
Since its inception, PhoreMost's model has been forging a new approach to drug discovery by working collaboratively with partners to advance new medicines. We are excited to announce this alliance with CCBT and inStem, which represents a milestone for PhoreMost and has tremendous potential to rapidly advance new treatments. "
Dr. Chris Torrance, CEO of PhoreMost
We are very pleased with the partnership between Phoremost and CCBT under the leadership of Professor Ashok Venkitaraman, and we look forward to the interesting results of this effort. "
Professor Apurva Sarin, Director, inStem
We are very pleased to announce this collaboration with PhoreMost. The ability of PhoreMost's SITESEEKER platform to identify leading drug targets as well as functional peptide ligands is very complementary to the structural biology capabilities of inStem and CCBT. We look forward to supporting drug discovery against these targets to advance the next generation of therapeutic products. "
Professor Satyajit Mayor, Director of CNBS and former Director of InStem
[ad_2]
Source link
